Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report
Immune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. However, ICIs may cause associated immune-related adverse events (ir-AEs). No case of sintilimab-induced toxic epid...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.989966/full |
| _version_ | 1828148355130195968 |
|---|---|
| author | Gang Li Sheng Gong Ning Wang Xiaojun Yao |
| author_facet | Gang Li Sheng Gong Ning Wang Xiaojun Yao |
| author_sort | Gang Li |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. However, ICIs may cause associated immune-related adverse events (ir-AEs). No case of sintilimab-induced toxic epidermal necrolysis (TEN) has been reported. In this report, we discussed a patient with advanced NSCLC and comorbid pulmonary tuberculosis who underwent immunotherapy and chemotherapy as neoadjuvant therapy and anti-tuberculosis therapy concurrently. Partial response (PR) of the tumor was achieved after three cycles of neoadjuvant therapy without cutaneous toxicities. Video-assisted thoracoscopic surgery (VATS) left lower lobectomy was performed successfully. Sintilimab and chemotherapy were administered as adjuvant therapy, after which the patient suffered severe TEN that rapidly progressed to cover >50% of the skin. TEN was associated with extensive rashes of the trunk and pruritus. With history of sintilimab use, clinical symptoms, and physical examination, TEN was diagnosed. Intravenous methylprednisolone and oral prednisone were administered until the patient totally recovered from the cutaneous toxicities caused by sintilimab. Monitoring of such rare but severe cutaneous toxicities is essential in patients who are treated with sintilimab. |
| first_indexed | 2024-04-11T21:14:47Z |
| format | Article |
| id | doaj.art-6699a620788345e29fc533d0ffa24b51 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-11T21:14:47Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-6699a620788345e29fc533d0ffa24b512022-12-22T04:02:51ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-08-011310.3389/fimmu.2022.989966989966Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case reportGang Li0Sheng Gong1Ning Wang2Xiaojun Yao3Department of Thoracic Surgery, The Public Health Clinical Center of Chengdu, Chengdu, ChinaDepartment of Thoracic Surgery, The Public Health Clinical Center of Chengdu, Chengdu, ChinaDepartment of Public Health, Chengdu Medical College, Chengdu, ChinaDepartment of Thoracic Surgery, The Public Health Clinical Center of Chengdu, Chengdu, ChinaImmune checkpoint inhibitors (ICIs) have had a revolutionary effect on the treatment of patients with advanced non-small cell lung cancer (NSCLC), especially squamous cell lung cancer. However, ICIs may cause associated immune-related adverse events (ir-AEs). No case of sintilimab-induced toxic epidermal necrolysis (TEN) has been reported. In this report, we discussed a patient with advanced NSCLC and comorbid pulmonary tuberculosis who underwent immunotherapy and chemotherapy as neoadjuvant therapy and anti-tuberculosis therapy concurrently. Partial response (PR) of the tumor was achieved after three cycles of neoadjuvant therapy without cutaneous toxicities. Video-assisted thoracoscopic surgery (VATS) left lower lobectomy was performed successfully. Sintilimab and chemotherapy were administered as adjuvant therapy, after which the patient suffered severe TEN that rapidly progressed to cover >50% of the skin. TEN was associated with extensive rashes of the trunk and pruritus. With history of sintilimab use, clinical symptoms, and physical examination, TEN was diagnosed. Intravenous methylprednisolone and oral prednisone were administered until the patient totally recovered from the cutaneous toxicities caused by sintilimab. Monitoring of such rare but severe cutaneous toxicities is essential in patients who are treated with sintilimab.https://www.frontiersin.org/articles/10.3389/fimmu.2022.989966/fullimmune-related adverse events (ir-AEs)neoadjuvant therapytoxic epidermal necrolysisnon-small cell lung cancerpulmonary tuberculosis |
| spellingShingle | Gang Li Sheng Gong Ning Wang Xiaojun Yao Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report Frontiers in Immunology immune-related adverse events (ir-AEs) neoadjuvant therapy toxic epidermal necrolysis non-small cell lung cancer pulmonary tuberculosis |
| title | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report |
| title_full | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report |
| title_fullStr | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report |
| title_full_unstemmed | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report |
| title_short | Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report |
| title_sort | toxic epidermal necrolysis induced by sintilimab in a patient with advanced non small cell lung cancer and comorbid pulmonary tuberculosis a case report |
| topic | immune-related adverse events (ir-AEs) neoadjuvant therapy toxic epidermal necrolysis non-small cell lung cancer pulmonary tuberculosis |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.989966/full |
| work_keys_str_mv | AT gangli toxicepidermalnecrolysisinducedbysintilimabinapatientwithadvancednonsmallcelllungcancerandcomorbidpulmonarytuberculosisacasereport AT shenggong toxicepidermalnecrolysisinducedbysintilimabinapatientwithadvancednonsmallcelllungcancerandcomorbidpulmonarytuberculosisacasereport AT ningwang toxicepidermalnecrolysisinducedbysintilimabinapatientwithadvancednonsmallcelllungcancerandcomorbidpulmonarytuberculosisacasereport AT xiaojunyao toxicepidermalnecrolysisinducedbysintilimabinapatientwithadvancednonsmallcelllungcancerandcomorbidpulmonarytuberculosisacasereport |